The companies Nycomed and Trenzyme, both situated in Konstanz, have signed multi-year cooperation agreement for services in the areas of molecular biology, protein expression, and protein purification.
As a service provider for Nycomed, Trenzyme will in future handle projects ranging from DNA-cloning and recombinant expression to protein purification.
The geographical proximity of the two companies allows for greater flexibility in responding to the scientific demands of projects and is thus considered a decisive factor for the success of this cooperation. The cooperation agreement therefore includes Trenzyme's relocation as an independent company to the Nycomed campus in Konstanz.
The Bodensee regional biotechnology association BioLAGO and the city of Konstanz welcome the cooperation. They see it as a successful example of the opportunities for corporate cooperation possible among the association's members. In such collaboration they recognise the opportunity to foster Life Science activity in the region together with Nycomed GmbH.
Nycomed is a pharmaceutical company that provides medicines for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets.
The company is active within a range of therapeutic areas, including cardiology, gastroenterology, osteoporosis, respiratory, pain and tissue management. New products are sourced both from own research and from external partners. Operating throughout Europe and in fast-growing markets such as Latin America, Russia/CIS and the Asia-Pacific region Nycomed has a presence in about 50 markets worldwide.
Privately owned, the combined group had annual sales of approximately € 3.4 billion and an EBITDA of € 933.4 million (2006 results).
For more information visit www.nycomed.com
As a service provider for Nycomed, Trenzyme will in future handle projects ranging from DNA-cloning and recombinant expression to protein purification.
The geographical proximity of the two companies allows for greater flexibility in responding to the scientific demands of projects and is thus considered a decisive factor for the success of this cooperation. The cooperation agreement therefore includes Trenzyme's relocation as an independent company to the Nycomed campus in Konstanz.
The Bodensee regional biotechnology association BioLAGO and the city of Konstanz welcome the cooperation. They see it as a successful example of the opportunities for corporate cooperation possible among the association's members. In such collaboration they recognise the opportunity to foster Life Science activity in the region together with Nycomed GmbH.
Nycomed is a pharmaceutical company that provides medicines for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets.
The company is active within a range of therapeutic areas, including cardiology, gastroenterology, osteoporosis, respiratory, pain and tissue management. New products are sourced both from own research and from external partners. Operating throughout Europe and in fast-growing markets such as Latin America, Russia/CIS and the Asia-Pacific region Nycomed has a presence in about 50 markets worldwide.
Privately owned, the combined group had annual sales of approximately € 3.4 billion and an EBITDA of € 933.4 million (2006 results).
For more information visit www.nycomed.com
